Product Description
CT7439 is a CDK12/13/Cyclin-K degrader, which potently inhibits the cellular activity of CDK12/13. CDK12/13 is implicated in multiple cancer types including breast, ovarian and Ewing's Sarcoma. (Sourced from: https://www.carricktherapeutics.com/pipeline/cdk1213-inhibitor)
Mechanisms of Action: CDK12 Degrader
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Carrick Therapeutics Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|